The Current State of Tinnitus Diagnosis and Treatment: a Multidisciplinary Expert Perspective

The paper addresses how tinnitus—a common condition affecting roughly 15% of the population, with about 2.4% experiencing significant distress—should be diagnosed and managed in clinical practice. It highlights the heterogeneity of tinnitus (including the recent distinction between tinnitus and tinnitus disorder) and emphasizes the complexity added by frequent comorbidities such as hyperacusis, insomnia, anxiety, and depression. The purpose is to synthesize current evidence, identify gaps and challenges, outline comprehensive diagnostic approaches, review treatment options and their evidentiary support, and reconcile differences across international guidelines. The importance lies in guiding multidisciplinary, patient-centered care in a field with no established curative therapy and substantial unmet clinical needs.

The authors provide a narrative review of the tinnitus field, covering: (1) shortcomings and challenges (lack of curative treatments, heterogeneity in clinical features and pathophysiology, absence of biomarkers and robust objective outcomes, variability in care, and limitations of animal models and mixed results from imaging/electrophysiology/genetics); (2) comprehensive diagnostic assessment emphasizing history, laterality and sound quality (pulsatile vs non-pulsatile), pure-tone audiometry (including ultrahigh frequencies), imaging where indicated (e.g., unilateral non-pulsatile tinnitus with asymmetric hearing loss, pulsatile tinnitus), assessment of psychological distress with validated questionnaires (THI, TFI), exploration of somatosensory modulation suggesting a somatic component, and screening for comorbidities; (3) a broad set of interventions including counselling, CBT, hearing aids, cochlear implants, sound therapy, auditory training, TRT, pharmacotherapy, neurofeedback, noninvasive brain stimulation (tDCS, rTMS), bimodal stimulation, physiotherapy/manual therapy for somatosensory tinnitus, complementary and alternative therapies, and digital/app-based approaches. Evidence summaries reference meta-analyses and guidelines (US 2014, European 2019, NICE 2020, German 2021), noting that CBT has the strongest evidence for reducing tinnitus-related distress; cochlear implants offer significant reduction in tinnitus for patients with severe hearing loss or single-sided deafness; hearing aids are recommended in those with hearing loss but RCT evidence for tinnitus-specific outcomes is mixed; sound therapies and individualized auditory stimulation lack consistent high-quality evidence; TRT shows mixed RCT results with possible long-term benefits; pharmacotherapies (e.g., antidepressants, anticonvulsants, betahistine, Ginkgo, zinc) show little to no benefit with guideline recommendations generally against their use for tinnitus per se; noninvasive brain stimulation shows small-to-moderate effect sizes but is not guideline-recommended; bimodal stimulation shows promising preliminary results; physiotherapy/manual therapy is promising in somatosensory tinnitus. The review also discusses differences and conservatism in guideline development and calls for larger, methodologically rigorous trials that consider tinnitus heterogeneity.

This is a multidisciplinary expert perspective and narrative review. The authors synthesize current knowledge from meta-analyses, Cochrane reviews, systematic reviews, randomized clinical trials, and multiple international guidelines (US 2014, European 2019, NICE 2020, German 2021). They complement evidence with clinical recommendations drawn from guideline summaries and their own clinical experience. No systematic review methods (e.g., predefined search strategy, risk-of-bias assessments) are reported. The paper includes an evidence summary table aligning interventions with evidence sources, efficacy, harms, and guideline recommendations to facilitate translation into clinical practice.

• Tinnitus is prevalent (~15%) with ~2.4% experiencing significant distress and frequent comorbidities, underscoring the need for multidisciplinary management.
• There is no proven curative treatment or reliably effective loudness-reducing therapy for most patients; objective biomarkers and outcome measures are lacking. Patient-reported questionnaires (e.g., THI, TFI) remain the gold-standard primary outcomes in trials.
• Comprehensive diagnostics should assess onset, laterality and sound quality (including pulsatile features), audiometry (including ultrahigh frequencies), imaging when indicated, psychological distress via standardized questionnaires, somatosensory modulation, and comorbidities (e.g., anxiety, depression, insomnia, hyperacusis, TMJ disorder, neck pain, headache); this informs individualized treatment planning.
• Counselling/psychoeducation is a foundational component recommended by all guidelines, though high-level RCT evidence is limited.
• Cognitive behavioral therapy (CBT) has the strongest evidence base for reducing tinnitus-related distress with minimal adverse effects; meta-analytic estimates show moderate effects on tinnitus severity (e.g., SMD around −0.56; THI reductions around −10.9), with comparable efficacy across face-to-face and internet-delivered formats.
• Hearing aids are guideline-recommended for individuals with tinnitus and clinically relevant hearing loss (to improve communication and potentially reduce tinnitus impact), although RCTs show no consistent tinnitus-specific benefit in the absence of significant hearing loss.
• Cochlear implants significantly reduce tinnitus in patients with severe hearing loss or single-sided deafness; meta-analytic data indicate large effects (e.g., SMD ≈ −1.32 on tinnitus scores). German guidelines strongly recommend cochlear implantation in appropriate candidates.
• Sound therapy (including sound generators) shows inconsistent evidence with no clear superiority over controls for tinnitus loudness or distress; some patients report situational benefit (e.g., masking for sleep or concentration). Many guidelines are cautious or recommend against specific sound generators; NICE prioritizes further research.
• Tinnitus Retraining Therapy (TRT) has mixed evidence; a major RCT found no superiority of full or partial TRT over standard care, while a meta-analysis suggests potential long-term benefits; guidelines vary (some recommend research or conditional consideration).
• Pharmacotherapy for tinnitus per se demonstrates little to no efficacy across drug classes (antidepressants, anticonvulsants, betahistine, Ginkgo biloba, zinc), with adverse effects possible (e.g., anticonvulsants side effects in ~18% of participants). Guidelines generally recommend against pharmacological treatments for tinnitus itself, while supporting treatment of comorbid conditions (e.g., insomnia, anxiety, depression).
• Noninvasive brain stimulation shows small-to-moderate short-term effects (e.g., tDCS SMD ≈ −0.35 for loudness, −0.5 for distress; rTMS SMD ≈ −0.45 immediate, −0.42 long-term on severity) but is currently not guideline-recommended; more rigorous evidence is needed.
• Bimodal stimulation (e.g., sound paired with tongue, face/neck, or vagus nerve stimulation) shows promising results in large trials and pilot studies, warranting further investigation.
• Physiotherapy and manual therapy may benefit patients with somatosensory tinnitus; early controlled studies are promising and call for systematic trials.
• There are notable inconsistencies across international guidelines due to varying evidentiary thresholds and conservatism; NICE explicitly highlights research gaps and prioritizes future studies.
• The field would benefit from decision support systems leveraging AI and large datasets to personalize treatment choices given tinnitus heterogeneity.

The review synthesizes evidence to address how clinicians can deliver patient-centered, evidence-based tinnitus care despite the absence of curative treatments and the condition’s heterogeneity. A comprehensive diagnostic framework identifies etiological factors, relevant pathophysiology, dominant sources of suffering, and comorbidities, enabling individualized treatment planning. Interventions with the strongest support—especially CBT—should be prioritized for reducing distress, with hearing rehabilitation (hearing aids and cochlear implants) selected based on the presence and severity of hearing loss. Other modalities (sound therapy, TRT, noninvasive brain stimulation, physiotherapy/manual therapy for somatosensory tinnitus, and bimodal stimulation) may be considered according to patient profiles, preferences, and evolving evidence. The authors emphasize balancing guideline recommendations with therapeutic freedom, transparent risk–benefit discussions (particularly for off-label or innovative treatments), and aligning care with patient goals (e.g., addressing insomnia or anxiety). They argue for “living” guidelines, methodologically rigorous and larger RCTs that account for heterogeneity, and development of AI-based decision support to predict treatment response.

The paper provides a multidisciplinary, practice-oriented synthesis of tinnitus diagnostics and treatments, highlighting CBT as the most evidence-based intervention to reduce distress, hearing rehabilitation for those with hearing loss (including cochlear implants for single-sided deafness or severe loss), and the importance of comprehensive, individualized assessment. It underscores major gaps: lack of curative therapies, objective biomarkers, and consistent evidence for many commonly used treatments. The authors call for: (1) larger, methodologically robust trials that stratify by tinnitus subtypes and comorbidities; (2) faster, “living” guideline updates and independent, methodologically driven guideline processes; (3) rigorous evaluation of promising innovations (bimodal stimulation, neurofeedback, individualized auditory stimulation, physiotherapy/manual therapy for somatosensory tinnitus); (4) development of AI-enabled decision support systems to personalize therapy; and (5) systematic inclusion of patient perspectives in guideline development and care pathways.

As a narrative expert perspective, the paper does not report systematic review methods and may be subject to selection and interpretive bias. The field’s evidence base is limited by heterogeneity of tinnitus, lack of validated biomarkers or objective outcomes, variable reliability of loudness measures, small sample sizes, short follow-up durations, and inconsistency across trials. Many interventions lack robust long-term efficacy data. Guideline development may be conservative and influenced by expert biases, and differences in healthcare systems further limit generalizability.